247 related articles for article (PubMed ID: 28963882)
1. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein.
Galan-Navarro C; Rincon-Restrepo M; Zimmer G; Ollmann Saphire E; Hubbell JA; Hirosue S; Swartz MA; Kunz S
Virology; 2017 Dec; 512():161-171. PubMed ID: 28963882
[TBL] [Abstract][Full Text] [Related]
2. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
3. Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.
Branco LM; Grove JN; Moses LM; Goba A; Fullah M; Momoh M; Schoepp RJ; Bausch DG; Garry RF
Virol J; 2010 Nov; 7():306. PubMed ID: 21062490
[TBL] [Abstract][Full Text] [Related]
4. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS
Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373
[TBL] [Abstract][Full Text] [Related]
7. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding.
Illick MM; Branco LM; Fair JN; Illick KA; Matschiner A; Schoepp R; Garry RF; Guttieri MC
Virol J; 2008 Dec; 5():161. PubMed ID: 19105844
[TBL] [Abstract][Full Text] [Related]
9. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
10. Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.
Borenstein-Katz A; Shulman A; Hamawi H; Leitner O; Diskin R
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728269
[TBL] [Abstract][Full Text] [Related]
11. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
12. Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization.
Acciani M; Alston JT; Zhao G; Reynolds H; Ali AM; Xu B; Brindley MA
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679759
[TBL] [Abstract][Full Text] [Related]
13. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.
Ibukun FI
Viruses; 2020 Mar; 12(4):. PubMed ID: 32244402
[TBL] [Abstract][Full Text] [Related]
14. Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.
Wang M; Li R; Li Y; Yu C; Chi X; Wu S; Liu S; Xu J; Chen W
Viruses; 2021 Mar; 13(3):. PubMed ID: 33804206
[TBL] [Abstract][Full Text] [Related]
15. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
[TBL] [Abstract][Full Text] [Related]
16. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
17. In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever.
Baral P; Pavadai E; Gerstman BS; Chapagain PP
Sci Rep; 2020 May; 10(1):7667. PubMed ID: 32376973
[TBL] [Abstract][Full Text] [Related]
18. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.
Enriquez AS; Buck TK; Li H; Norris MJ; Moon-Walker A; Zandonatti MA; Harkins SS; Robinson JE; Branco LM; Garry RF; Saphire EO; Hastie KM
Cell Rep; 2022 May; 39(8):110841. PubMed ID: 35613585
[TBL] [Abstract][Full Text] [Related]
19. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Perrett HR; Brouwer PJM; Hurtado J; Newby ML; Liu L; Müller-Kräuter H; Müller Aguirre S; Burger JA; Bouhuijs JH; Gibson G; Messmer T; Schieffelin JS; Antanasijevic A; Boons GJ; Strecker T; Crispin M; Sanders RW; Briney B; Ward AB
Cell Rep; 2023 May; 42(5):112524. PubMed ID: 37209096
[TBL] [Abstract][Full Text] [Related]
20. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
